The combination of CTLA-4 and PD-1 blockers increases the response rates in patients, and ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) in combination are particularly effective in different cancer types, such as those affecting the kidney [100]. This evidence concerns the gene CTLA4 and cancer.